These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30831041)

  • 21. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
    Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
    Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
    Nakano K; Motoi N; Inagaki L; Tomomatsu J; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Jpn J Clin Oncol; 2015 May; 45(5):449-55. PubMed ID: 25724217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
    Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
    Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
    [No Abstract]   [Full Text] [Related]  

  • 28. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
    Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
    Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
    Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
    [No Abstract]   [Full Text] [Related]  

  • 30. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
    Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
    J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
    Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
    Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Acid-Suppressive Strategies on Pazopanib Efficacy in Patients With Soft-Tissue Sarcoma.
    Pisano SG; Hoffman SE; Legasto CS; McLaughlin EM; Porter K; Chen JL
    Clin Transl Sci; 2019 Sep; 12(5):529-533. PubMed ID: 31264782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04).
    Ronellenfitsch U; Karampinis I; Dimitrakopoulou-Strauss A; Sachpekidis C; Jakob J; Kasper B; Nowak K; Pilz L; Attenberger U; Gaiser T; Derigs HG; Schwarzbach M; Hohenberger P
    Ann Surg Oncol; 2019 May; 26(5):1332-1339. PubMed ID: 30843160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
    Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
    Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
    Teshima Y; Nomura S; Fukasawa N
    Jpn J Clin Oncol; 2021 Apr; 51(4):612-621. PubMed ID: 33283234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.